Bone Care Injectable Hectorol Approved After "Filing Over Protest"
This article was originally published in Pharmaceutical Approvals Monthly
Executive Summary
Bone Care International’s "file-over-protest" strategy for injectable Hectorol (doxercalciferol) resulted in approval of the vitamin D replacement therapy on April 6, exactly one year after the NDA was submitted over FDA’s objection.